Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. — CFSMEATLAS
Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts.
Bynke, Annie, Julin, Per, Gottfries, Carl-Gerhard et al. · Brain, behavior, & immunity - health · 2020 · DOI
Quick Summary
Researchers tested blood and spinal fluid samples from ME/CFS patients and healthy people to look for certain antibodies (immune proteins) that mistakenly attack nerve receptors in the body. They found higher levels of some of these antibodies in ME/CFS patients compared to healthy controls, particularly antibodies targeting muscarinic receptors (involved in nerve signaling). However, the amount of these antibodies did not match how severe patients' symptoms were.
Why It Matters
This study provides validation that autoantibody abnormalities exist in ME/CFS, potentially supporting the hypothesis that autoimmune mechanisms contribute to disease pathogenesis. Understanding whether these antibodies drive symptoms could open new diagnostic and treatment avenues for patients with this debilitating condition.
Observed Findings
Significantly elevated M3 and M4 muscarinic receptor autoantibodies in ME patients compared to controls across both cohorts
Elevated β1, β2, M3, and M4 receptor autoantibodies in one of the two patient cohorts
No significant autoantibody levels detected in cerebrospinal fluid (CSF) samples from ME patients
No statistically significant correlation between autoantibody levels and disease severity questionnaire scores
Validation of previously reported increased autoantibody patterns in the ME patient population
Inferred Conclusions
A consistent pattern of increased adrenergic and muscarinic receptor autoantibodies exists in ME/CFS patients, supporting previous findings
These autoantibodies may represent immune system dysregulation characteristic of ME/CFS but their direct pathogenic role remains uncertain
The lack of CSF autoantibodies suggests blood-brain barrier restriction or that central nervous system involvement is not primary
Further research is needed to determine whether these autoantibodies are pathogenic, epiphenomena, or biomarkers of underlying disease mechanisms
Remaining Questions
Do these autoantibodies functionally impair adrenergic and muscarinic receptor signaling, and could they directly cause autonomic or cognitive symptoms?
What This Study Does Not Prove
This study does not prove that these autoantibodies actually cause ME/CFS symptoms or are pathologically significant—it only shows they are present at higher levels. The absence of correlation with disease severity and lack of CSF findings suggest these autoantibodies may not directly explain symptom severity. Observing autoantibodies does not establish causation or clarify their functional role in disease mechanisms.